1 Min Read
* LA JOLLA PHARMACEUTICAL COMPANY ANNOUNCES INITIATION OF PIVOTAL CLINICAL STUDY OF LJPC-401 IN PATIENTS WITH BETA THALASSEMIA Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.